We believe that working relationships with global partners is essential to helping more patients get the treatments that they need. Our collaboration with Ora is a perfect example.
RevOpsis, an innovative provider of multitarget therapeutics on the Rev-Mod platform, has entered into a strategic partnership with Ora, Inc., a world leading full-service ophthalmic drug and device development firm to develop a Trispecific for Neovascular Macular Degeneration. This collaboration will enable RevOpsis to leverage Ora's unparalleled expertise and proven track record to streamline and optimize the development of ophthalmic innovations.
Ora's extensive experience spanning over four decades has been instrumental in securing over 80 product approvals across a diverse range of ophthalmic therapies, encompassing Retina, Glaucoma, Dry Eye, Allergy, Presbyopia, Anti-infective and Device applications. Their expertise leverages pre-clinical and clinical models, unique methodologies, and global regulatory strategies, refined and validated through thousands of global projects. Ora brings together the world’s most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives.
The Ora Posterior Segment Division, the fastest-growing department within Ora, boasts a global operations team of over 100 individuals and has therapeutic experts with extensive experience in a wide array of retinal indications. Over the past five years, the Ora retina team has conducted over 45 retina trials, including Wet and Dry Age Related Macular Degeneration (including Geographic Atrophy), Diabetic Eye Disease and Inherited Retinal Disease research across 240+ sites in the US, Europe, Asia, and LATAM for Phase 0, 1, 2, and 3 programs.
This strategic partnership ensures that RevOpsis has direct access to Ora's ophthalmic expertise throughout the development process, providing valuable guidance on IND enabling work, regulatory strategy, and clinical development planning. This collaboration will undoubtedly minimize clinical risks and increase the likelihood of successful product pipeline advancement.
RevOpsis is committed to providing the most comprehensive and innovative solutions for ophthalmic product development. By partnering with Ora, RevOpsis further strengthens its capabilities and reaffirms its dedication to accelerating the development of life-changing ophthalmic therapies.